BioMarin Pharmaceutical Inc.

Total Valuation

BioMarin Pharmaceutical Inc. carries a market capitalization of 11.44B, placing it among publicly traded companies globally. Its enterprise value stands at 10.07B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

BioMarin Pharmaceutical Inc. currently has 193.27M shares outstanding.

Valuation Ratios

BioMarin Pharmaceutical Inc. trades at a trailing price-to-earnings ratio of 40.39. The price-to-sales ratio is 3.35, and the price-to-book ratio stands at 41.76.

Enterprise Valuation

On an enterprise value basis, BioMarin Pharmaceutical Inc. trades at an EV/EBITDA multiple of 25.89 and an EV/FCF ratio of 10.02. The EV/Sales ratio of 3.11 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 31.95 provides insight into valuation relative to core operating earnings.

Financial Position

BioMarin Pharmaceutical Inc. maintains a current ratio of 5.81, meaning it holds 5.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 23.17, indicating elevated leverage, while an interest coverage ratio of 16.92 demonstrates strong ability to service its debt obligations.

Financial Efficiency

Taxes

Over the trailing twelve months, BioMarin Pharmaceutical Inc. has paid 116.85M in income taxes, reflecting an effective tax rate of 30.30.

Stock Price Statistics

BioMarin Pharmaceutical Inc.'s stock has gained approximately 4.68529% over the past 52 weeks. The 50-day moving average sits at 55.91, while the 200-day moving average is 56.04.

Income Statement

Over the trailing twelve months, BioMarin Pharmaceutical Inc. generated 3.24B in revenue and converted that into 268.74M in net income, yielding earnings per share of 1.38. EBITDA reached 389.12M, while operating income came in at 315.22M.

Balance Sheet

BioMarin Pharmaceutical Inc. holds 2.22B in cash and equivalents against 1.44B in total debt, resulting in a net debt position of -792.15M. Total book value stands at 259.93M, with working capital of 3.81B providing operational flexibility.

Cash Flow

BioMarin Pharmaceutical Inc. produced 874.25M in operating cash flow over the past twelve months. After subtracting -115.13M in capital expenditures, free cash flow totaled 759.12M - equivalent to 3.95 per share.

Margins

BioMarin Pharmaceutical Inc. operates with a gross margin of 76.53, reflecting its pricing power and cost economics. The operating margin of 9.72 and net profit margin of 8.29 provide insight into operational efficiency.

Dividends & Yields

Scores

BioMarin Pharmaceutical Inc. posts an Altman Z-Score of 3.86, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.